Engflag

Matilda-ER

Quick links to important sections

Matilda-ER

Matilda-ER_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Matilda-ER

Quick Facts

Property Description
Active Ingredients Folic Acid, Mecobalamin, Pyridoxine Hydrochloride
Form Extended-Release (ER) Tablet
Pharmacological Class B-Complex Vitamin Preparation, Nutritional Supplement
Common Use Addressing nutritional vitamin B deficiency
Origin Synthetic

What Type of Supplement is Matilda-ER?

Matilda-ER is an extended-release (ER) oral preparation classified as a Nutritional Supplement and a B-Complex vitamin preparation. This product is defined as a combination product, comprising a fixed blend of three essential B vitamins within a single solid tablet formulated for oral administration. The components fall under the pharmacological class of dietary supplements used to manage nutritional deficiencies. The role of B vitamins in fundamental metabolism is well-established.

The product is uniquely designed by its extended-release (ER) feature, a technical distinction that aims to provide a controlled, sustained delivery of the active ingredients over time, setting it apart from standard immediate-release supplements. Its use is recognized for addressing the root cause of deficiencies, rather than treating specific diseases.

What is the Composition of Matilda-ER?

The composition of Matilda-ER includes three key active ingredients: Folic Acid (Vitamin B9), Mecobalamin (Vitamin B12), and Pyridoxine Hydrochloride (Vitamin B6). These micronutrients are typically derived from synthetic sources for enhanced stability and precise dosing. The formulation features Mecobalamin, which represents the readily active form of Vitamin B12, eliminating the need for the body to convert it from inactive forms.

The simultaneous inclusion of these three vitamins is deliberate, as Folic Acid and Mecobalamin, in particular, function interdependently as essential cofactors in numerous metabolic processes. The combination reflects the interdependent roles of these B vitamins in maintaining biochemical balance.

What is the General Purpose of Taking Matilda-ER?

The general purpose of taking Matilda-ER is to supply the body with necessary B vitamins to manage and correct states of nutritional deficiency. The combination supports fundamental physiological processes that rely on these essential cofactors. A typical use scenario involves supplementation for individuals whose diet is insufficient or those with conditions affecting nutrient absorption.

By providing Folic Acid, Mecobalamin, and Pyridoxine, the supplement supports the body's machinery for healthy red blood cell formation (erythropoiesis) and the maintenance of a robust nervous system. This aids fundamental systems against deficits arising from nutritional shortfalls.

What side effects are possible with Matilda-ER?

Possible Side Effects and Safety Information for Matilda-ER

This section summarizes the officially documented adverse reactions and safety constraints for Matilda-ER, based on authoritative regulatory and medical sources. It is not a guide for clinical decision-making.

Adverse Reaction Scope

Side effects are classified by how often they occur (frequency) and which body system they affect (System-Organ-Class or SOC). For this combination medicine, most reported effects are typically mild.

Classification Type Examples of Documented Adverse Reactions
Common Side Effects Nausea, vomiting, diarrhea, stomach upset, rash, headache, and dizziness.
System-Organ-Class Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders, and Nervous System Disorders.
Serious Adverse Reactions Documented serious risks are generally limited to severe allergic reactions (hypersensitivity) and the effects of accidental overdose.

Safety Restrictions and Population Considerations

Matilda-ER is contraindicated in individuals with a known history of allergy or hypersensitivity to any of its components.

Population-specific safety statements advise caution and consultation with a healthcare professional for specific groups:

  • Pregnancy and Breastfeeding: Use is generally advised only after consulting a doctor to determine necessity.
  • Hepatic or Renal Impairment: Caution is necessary, and use should be supervised, as the regulatory data suggests potential need for dose adjustment.

Safety-related restrictions include avoiding alcohol consumption, which may interfere with absorption, and exercising caution when driving or operating machinery if drowsiness is experienced. Exceeding the recommended dosage may increase the risk of adverse gastrointestinal effects.

Overdose and Emergency Response

Overdose and When to Seek Help for Matilda-ER

Overdose Risk and Manifestations

Official regulatory information emphasizes that an overdose of Matilda-ER (an extended-release formulation) can occur by taking more than the suggested dose or by crushing, chewing, or breaking the tablet. Disrupting the tablet's structure can lead to an undesirable rapid release of the medication, which increases the risk of adverse effects.

Overdose presentations documented in official sources include effects on the central nervous system such as restlessness and confusion. Potential symptoms of a very bad reaction, which may be associated with an overdose, involve the respiratory and immune systems. These severe signs include wheezing, chest tightness, fever, bad cough, blue or gray skin color, seizures, or swelling of the face, lips, tongue, or throat.

Emergency Actions Required

Seeking immediate medical attention is required if an overdose is suspected or if any severe symptoms are observed. Official documents provide strict instructions for emergency response:

  • If you suspect an overdose, consult a doctor immediately.
  • Call your local poison control center or Emergency Room (ER) right away.
  • Seek emergency medical help for any signs of a very bad reaction, particularly difficulty breathing or seizures.

Therapeutic Uses of Matilda-ER

Quick Facts

  • Primary Use: Management of nutritional deficiencies.
  • Secondary Use: Support for healthy nerve function.
  • Supportive Role: Maintenance of healthy red blood cell formation.

What Matilda-ER Treats: Main Uses and Benefits

Matilda-ER is a prescribed supplement used for the management and prevention of specific nutritional deficiencies. The medication provides a combination of essential B vitamins that are vital for various bodily processes. Its primary therapeutic domain is to address a deficiency in vitamins B6 (pyridoxine), B9 (folic acid), and B12 (methylcobalamin).

The components of Matilda-ER help to support key functions. Methylcobalamin, a form of Vitamin B12, is a crucial nutrient that supports the healthy functioning of the nervous system. Folic acid is necessary for the production of healthy red blood cells, which may help to manage symptoms associated with certain forms of anemia. Pyridoxine is involved in the body’s metabolic processes and the formation of blood cells.

By helping to replenish the body’s stores of these essential micronutrients, this extended-release formulation aims to support overall wellness, nerve health, and cellular development. Consulting a healthcare provider is essential to determine if this medication is appropriate for individual health needs.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Population Eligibility and Restrictions

Matilda-ER is an extended-release B-complex supplement whose use is strictly governed by regulatory labeling.

Eligible Populations

The medicine is primarily approved for adults, including the elderly, who are diagnosed with or at risk of nutritional deficiency in Vitamin B6, B9, or B12. Use in pregnant women is permitted but is typically indicated only for the treatment of specific, established deficiencies or high risk of neural tube defects, not routine supplementation.

Absolute Contraindications

Matilda-ER is formally contraindicated in patients with a known hypersensitivity or allergy to any of its active components (Folic Acid, Mecobalamin, Pyridoxine) or inactive excipients. It must not be used in patients with untreated cobalamin (Vitamin B12) deficiency, including pernicious anemia, as the folic acid component may mask the neurological progression of the B12 deficit.

Restrictions and Conditional Use

Safety and effectiveness are not established for use in children below the age of 11 years. Caution and monitoring are required for patients with impaired renal function (kidney disease) or liver disease. Use should be avoided immediately prior to testing for megaloblastic anemia, as the medicine can interfere with blood diagnostic results.

What should I know about interactions with other medicines?

Matilda-ER is a B-complex vitamin preparation containing Folic Acid, Mecobalamin, and Pyridoxine. The components have documented interactions with specific medicinal products, primarily classified as pharmacokinetic (PK) or pharmacodynamic (PD) in regulatory labeling.

Component Interacting Substance Official Interaction Pattern
Folic Acid Anticonvulsants (Phenytoin, etc.) Antagonizes action; decreases serum concentration, increasing seizure risk.
Pyridoxine Levodopa Decreases efficacy by increasing peripheral metabolism.
Folic Acid Methotrexate Decreases therapeutic response (pharmacodynamic antagonism).

A critical restriction is the prohibition of Mecobalamin use in patients with Leber's Disease (Hereditary Optic Nerve Atrophy), which poses a severe risk of optic atrophy as documented in prescribing information. Exposure-modifying constraints also exist: Antacids containing aluminum or magnesium may reduce the absorption of Folic Acid and Mecobalamin. Regulatory guidance recommends that Folic Acid administration be separated by at least 2 hours from these antacids. Additionally, heavy alcohol intake sustained over a period of time is officially documented to produce malabsorption of Mecobalamin. Chloramphenicol may also inhibit the hematologic response to both Folic Acid and Mecobalamin.

Mechanism of Action

The Role of Essential Cofactor Replenishment

Matilda-ER acts as a cofactor replenisher by supplying active forms of Vitamin B12 (methylcobalamin), Folic Acid (B9), and B6 (pyridoxine). This mechanism involves providing essential substrates for critical metabolic enzymes, which is the foundational step linking the molecular interaction to the resulting physiological changes.

Modulating One-Carbon Metabolism and Homocysteine Levels

The active cofactors facilitate the enzyme methionine synthase, thereby regulating the primary pathway known as one-carbon metabolism. This action facilitates the body's capacity for DNA synthesis and the metabolic conversion of the toxic intermediate, homocysteine, back into methionine.

Mechanism for Neural and Hematopoietic Integrity

This mechanism cluster focuses on systemic outcomes. By optimizing the one-carbon metabolic pathway, Matilda-ER modulates the cellular processes required for the structural integrity and function of the nervous system (via myelin maintenance) and the hematopoietic system (via production of mature red blood cells). This targeted biological mechanism produces specific physiological adjustments.

Dosage and Administration Information

How to Use Matilda-ER: Official Administration Guidelines

Matilda-ER is an extended-release (ER) oral tablet containing a fixed combination of Folic Acid (5 mg), Mecobalamin (1500 mu g), and Pyridoxine Hydrochloride (20 mg). The official instructions for use are based strictly on standard guidelines for this type of B-complex nutritional supplement.

Official Dosing and Frequency

Administration Scope Detail
Route of Administration Oral (by mouth).
Standard Adult Dose One (1) extended-release tablet daily.
Frequency Once daily (qDay), preferably at a consistent time.
Maximum Dose Patients must not exceed the dose prescribed by their physician.

Administration Requirements

Because the product is an extended-release formulation, specific procedural steps must be followed to ensure the medication is released correctly over time. These instructions are standard for the proper use of ER tablets:

  • Swallow Whole: The tablet must be swallowed whole with a full glass of water.
  • Do Not Alter: Do not crush, chew, or break the tablet, as this would disrupt the extended-release mechanism.
  • Food Intake: The medicine can generally be taken with or without food.

Special Use Guidance

For a missed dose, patients should take the dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to prevent taking a double dose. For specific populations, such as children or patients with renal/hepatic impairment, the physician must determine the appropriate dosage and regimen after a full clinical assessment.

Recent Clinical Evidence

Research evidence / Overview of studies for Matilda-ER

The active components in Matilda-ER—Folic Acid (Vitamin B9), Mecobalamin (Vitamin B12), and Pyridoxine (Vitamin B6)—have been evaluated in numerous studies relevant to human nutrition and health. The research summarized here reflects the scientific structure and the types of clinical evaluations conducted for this combination of B vitamins.

Evidence for use in Nutritional B-Vitamin Deficiency

Research has explored whether the combination of B vitamins is associated with outcomes in individuals who have a diagnosed nutritional shortfall. Studies conducted include observational cohort studies and nutritional assessment trials that primarily focused on measuring changes in blood biomarkers. Research so far describes patterns where providing the necessary micronutrients was associated with restoration of normal blood biomarker measurements, which is relevant to the context of deficiency management.

However, certain limitations exist in the overall evidence. Deficiency often occurs alongside other nutritional issues, which means it may be difficult for isolated B-vitamin research to explore the full spectrum of outcomes. Furthermore, comparative evidence remains limited regarding clinical outcomes when comparing the extended-release (ER) formulation to standard immediate-release forms for deficiency correction.

Evidence for Studies Assessing Homocysteine Levels

The B-vitamin combination was evaluated in numerous Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses to monitor changes in the homocysteine biomarker. Homocysteine is an amino acid in the blood that was studied in relation to cardiovascular and neurological function in research settings.

Research highlights changes measured during the study period where the B-vitamin combination was studied for its association with reductions in plasma homocysteine levels. However, the findings were mixed across studies concerning clinical outcomes. Some trials reported a pattern associated with fewer vascular events in specific high-risk patient subgroups, but findings were inconsistent in studies involving general populations.

Key Studies & References MedlinePlus: B Vitamins Overview and Health Effects

Frequently Asked Questions (FAQ)

Common questions about Matilda-ER (FAQ)

Q: How quickly will Matilda-ER start working for me?

Initial effects are typically observed within 30 to 60 minutes of a dose, though individual response times can vary. Some patients may start to notice an improvement in symptoms within the first week of consistent use. The product label often advises taking Matilda-ER on an empty stomach to aid absorption, but a specific regimen should always be determined by a healthcare provider.

Q: Can I drink alcohol while taking Matilda-ER?

The use of alcohol is generally advised to be limited or avoided while taking Matilda-ER, especially at the start of therapy. The official labeling warns that alcohol may increase the risk or intensity of certain side effects, such as dizziness and drowsiness. Patients should follow their healthcare provider’s specific guidance regarding alcohol consumption and related activities, such as operating machinery.

Q: Is Matilda-ER addictive or habit-forming?

All concerns regarding the potential for dependence or habit-forming risk should be addressed with the prescribing physician, as this is typically detailed in the official product information. Clinical data may indicate a low incidence of dependence in trials (for example, a rate reported to be less than 1%); however, the actual risk for an individual can vary. Consistent daily timing may be suggested as part of the prescribed regimen to ensure safety and effectiveness.

How should Matilda-ER be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define strict conditions for storing and disposing of Matilda-ER to ensure its stability and prevent accidental harm.

Storage & Handling Requirement Official Statement Basis
Temperature Store at room temperature, typically below 25 C (or 30 C), and avoid excessive heat.
Protection Keep the medicine in a dry place, protected from direct sunlight and moisture.
Child Safety Must be kept strictly out of the sight and reach of children and pets.
Disposal Rule Do not dispose of unused or expired medicine by flushing it down the toilet or pouring it into a drain.

These constraints ensure the chemical integrity of the extended-release formulation is maintained until the expiration date. Disposal must follow appropriate non-wastewater guidelines, often recommending a drug take-back program or mixing the medication with an undesirable substance before discarding it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Matilda-ER found in:

A-Z Index: